Scott Haake, MD, PhD is Assistant Professor of Medicine within the Department of Medicine and the Division of Hematology/Oncology at Vanderbilt University Medical Center. Dr. Haake is a kidney cancer-focused investigator and leads a research team focused on tumor cell interaction with the extracellular matrix, integrin signaling, biomarker development, and kidney cancer biology. Dr. Haake’s work spans multiple projects, including basic cancer biology research, animal models of cancer, translational work in human tissues and clinical trials. His work is funded by the National Cancer Institute, the Kure It Foundation, and the Department of Defense Kidney Cancer Research Program.

Dr. Haake has been awarded Young Investigator Awards by the American Association of Cancer Research (2015) and the Kidney Cancer Association (2019). He has also received a Research Scholars Award from the American Urological Association (2016). In 2008 he was elected to the Alpha Omega Alpha national medical honor society during his junior year of medical school. In 2005, Haake received the King-O’Neal Scholar Award, an award reserved for those graduating first in their class at the University of South Florida.

After graduating from the University of South Florida with honors (summa cum laude) with a degree in biomedical sciences in 2005, Haake earned a Medical Degree from the University of Miami School of Medicine in 2009. He completed internal medicine training at the University of North Carolina in Chapel Hill, NC (2011) and hematology/oncology fellowship at H. Lee Moffitt Cancer Center in Tampa, FL (2015). He was subsequently recruited to Vanderbilt University Medical Center as an Instructor of Medicine. He was promoted to Assistant Professor in 2020 and completed a Ph.D. in Cancer Biology from Vanderbilt University in 2022. He has authored or co-authored approximately 20 articles published din the peer-reviewed scientific literature. In addition to his current funding, his research has previously been funded by the Conquer Cancer Foundation, American Urological Association, the Vanderbilt Clinical Oncology Research Career Development Program, the Kidney Cancer Association, and the Vanderbilt Institute for Clinical and Translational Research.